Lyn M. Moir

1.4k total citations
39 papers, 1.2k citations indexed

About

Lyn M. Moir is a scholar working on Physiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lyn M. Moir has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Physiology, 14 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lyn M. Moir's work include Asthma and respiratory diseases (17 papers), Tuberous Sclerosis Complex Research (7 papers) and Cell Adhesion Molecules Research (6 papers). Lyn M. Moir is often cited by papers focused on Asthma and respiratory diseases (17 papers), Tuberous Sclerosis Complex Research (7 papers) and Cell Adhesion Molecules Research (6 papers). Lyn M. Moir collaborates with scholars based in Australia, United Kingdom and United States. Lyn M. Moir's co-authors include Janette K. Burgess, Judith L. Black, Brian G. Oliver, Stuart J. Hirst, Qi Ge, Trang T.B. Nguyen, Thomas Trian, Matthew P. Hallsworth, Paul M. Young and Daniela Traini and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Lyn M. Moir

38 papers receiving 1.1k citations

Peers

Lyn M. Moir

PHYSI

PRM

IMMUN

ONCOL

Evan Boetticher United States

Teruaki Nishiuma Japan

Elena P. Moiseeva United Kingdom

Mark F. Lawson United Kingdom

Xuan Qu United States

Soo‐Youl Kim South Korea

Eui Man Jeong South Korea

Mika Terao Japan

Bonnie Seidel-Rogol United States

Zhiqing Li China

Evan Boetticher United States

Lyn M. Moir

336 ×0.6

PHYSI

138 ×0.3

PRM

437 ×1.2

302 ×1.3

IMMUN

64 ×0.5

ONCOL

Citations per year, relative to Lyn M. Moir Lyn M. Moir (= 1×) peers Evan Boetticher

Countries citing papers authored by Lyn M. Moir

Since Specialization

Citations

This map shows the geographic impact of Lyn M. Moir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lyn M. Moir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lyn M. Moir more than expected).

Fields of papers citing papers by Lyn M. Moir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lyn M. Moir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lyn M. Moir. The network helps show where Lyn M. Moir may publish in the future.

Co-authorship network of co-authors of Lyn M. Moir

This figure shows the co-authorship network connecting the top 25 collaborators of Lyn M. Moir. A scholar is included among the top collaborators of Lyn M. Moir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lyn M. Moir. Lyn M. Moir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Ruo‐Qian, et al.. (2022). Prospective nanoparticle treatments for lymphangioleiomyomatosis. Expert Opinion on Drug Delivery. 19(1). 75–86.

Reis, Larissa Gomes dos, Wing‐Hin Lee, Lyn M. Moir, et al.. (2020). Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. Drug Development and Industrial Pharmacy. 46(3). 427–442. 21 indexed citations

Moir, Lyn M., et al.. (2019). Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis. European Journal of Pharmaceutical Sciences. 142. 105098–105098. 20 indexed citations

Reis, Larissa Gomes dos, Wing‐Hin Lee, Lyn M. Moir, et al.. (2019). Nanotoxicologic Effects of PLGA Nanoparticles Formulated with a Cell-Penetrating Peptide: Searching for a Safe pDNA Delivery System for the Lungs. Pharmaceutics. 11(1). 12–12. 32 indexed citations

Reis, Larissa Gomes dos, et al.. (2018). Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer. Pharmaceutical Research. 36(1). 14–14. 7 indexed citations

Moir, Lyn M.. (2015). Lymphangioleiomyomatosis: Current understanding and potential treatments. Pharmacology & Therapeutics. 158. 114–124. 26 indexed citations

Haghi, Mehra, Lyn M. Moir, Bing Zhu, et al.. (2015). Inhalable tranexamic acid for haemoptysis treatment. European Journal of Pharmaceutics and Biopharmaceutics. 93. 311–319. 17 indexed citations

Baker, Katie, Sara J. Bonvini, Chantal Donovan, et al.. (2014). Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models. Pulmonary Pharmacology & Therapeutics. 29(2). 181–198. 20 indexed citations

Moir, Lyn M., Judith L. Black, Nicole G. Hansbro, et al.. (2014). LF-15 & T7, Synthetic Peptides Derived from Tumstatin, Attenuate Aspects of Airway Remodelling in a Murine Model of Chronic OVA-Induced Allergic Airway Disease. PLoS ONE. 9(1). e85655–e85655. 10 indexed citations

10.

Weckmann, Markus, Lyn M. Moir, Caroline A. Heckman, et al.. (2012). Lamstatin – a novel inhibitor of lymphangiogenesis derived from collagen IV. Journal of Cellular and Molecular Medicine. 16(12). 3062–3073. 22 indexed citations

11.

Xia, Yuxiu, Naresh Singh Redhu, Lyn M. Moir, et al.. (2012). Pro-inflammatory and immunomodulatory functions of airway smooth muscle: Emerging concepts. Pulmonary Pharmacology & Therapeutics. 26(1). 64–74. 40 indexed citations

12.

Yeganeh, Behzad, Subhendu Mukherjee, Lyn M. Moir, et al.. (2012). Novel non-canonical TGF-β signaling networks: Emerging roles in airway smooth muscle phenotype and function. Pulmonary Pharmacology & Therapeutics. 26(1). 50–63. 40 indexed citations

13.

Siddiqui, Sana, Naresh Singh Redhu, Oluwaseun O. Ojo, et al.. (2012). Emerging airway smooth muscle targets to treat asthma. Pulmonary Pharmacology & Therapeutics. 26(1). 132–144. 28 indexed citations

14.

Trian, Thomas, Janette K. Burgess, Kyoko Niimi, et al.. (2011). β2-Agonist Induced cAMP Is Decreased in Asthmatic Airway Smooth Muscle Due to Increased PDE4D. PLoS ONE. 6(5). e20000–e20000. 70 indexed citations

15.

Moir, Lyn M., Janette K. Burgess, Stephen B. Liggett, et al.. (2011). Beta2-Agonist Induced Camp Is Decreased In Asthmatic Airway Smooth Muscle Due To Increased PDE4D. UTS ePRESS (University of Technology Sydney). A2075–A2075. 18 indexed citations

16.

Oliver, Brian G., Melissa Baraket, Emma Beckett, et al.. (2010). Fibulin-1 Is Increased in Asthma – A Novel Mediator of Airway Remodeling?. PLoS ONE. 5(10). e13360–e13360. 41 indexed citations

17.

Burgess, Janette K., Sarah Boustany, Lyn M. Moir, et al.. (2009). Reduction of Tumstatin in Asthmatic Airways Contributes to Angiogenesis, Inflammation, and Hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine. 181(2). 106–115. 58 indexed citations

18.

Trian, Thomas, Lyn M. Moir, Qi Ge, et al.. (2009). Rhinovirus-Induced Exacerbations of Asthma. American Journal of Respiratory Cell and Molecular Biology. 43(2). 227–233. 26 indexed citations

19.

Ammit, Alaina J., Lyn M. Moir, Brian G. Oliver, et al.. (2006). Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. American Journal of Physiology-Lung Cellular and Molecular Physiology. 292(1). L199–L206. 56 indexed citations

20.

Hallsworth, Matthew P., et al.. (2001). Inhibitors of Mitogen-activated Protein Kinases Differentially Regulate Eosinophil-activating Cytokine Release from Human Airway Smooth Muscle. American Journal of Respiratory and Critical Care Medicine. 164(4). 688–697. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact